Consequently, inhibition of Grp94 holds promise as a therapy to treat myocilin-associated glaucoma21–23,25 by preventing its toxic gain-of-function—accumulation in cells—as the absence of myocilin in humans26 or mice27 does not lead to glaucoma. This evidence concerns the gene MYOC and glaucoma.